secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2023-08-16T23:59:59+00:00
Accession:  0001193125-23-213940
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno Therapeutics appoints Matthew Pauls to Board, expanding to seven directors
--------------------------------------------------------------------------------

- Board increased to seven; Matthew Pauls appointed as Class II director effective August 15, 2023, term expiring 2026.
- Pauls brings 30+ years biopharma experience; currently CEO of Savara Inc. (NASDAQ: SVRA) and former CEO of Strongbridge Biopharma.
- Granted option for 15,000 shares vesting monthly over 4 years under the Company's 2014 equity plan.
- Appointment comes as Soleno advances DCCR for Prader-Willi syndrome toward planned regulatory filing and potential approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312523213940/0001193125-23-213940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312523213940/d523594d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-213940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer